Harvard Apparatus Cm (HART) 1.79 $HART
Harvard Apparatus Regenerative Technology Changes Name to Biostage, Inc. (NASDAQ: BSTG)
PR Newswire - Thu Mar 31, 7:00AM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART) announced today it has changed its corporate name to Biostage, Inc. and will trade under the Nasdaq symbol "BSTG" effective April 1, 2016. Concurrently, the company has launched a new web site www.biostage.com to provide greater clarity and visibility for its technology.
HART: 1.79 (+0.14)
Bioengineered Organ Implant Developer HART Reviews Progress and Q4 2015 Results
PR Newswire - Thu Mar 17, 3:21PM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), announced its financial results for the fourth quarter and year ended December 31, 2015 and reviewed its corporate and research progress and plans.
HART: 1.79 (+0.14)
Bioengineered Organ Implant Developer HART Names Accomplished Biotechnology Executive Dr. Blaine McKee to its Board
PR Newswire - Thu Mar 10, 10:06AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today announced the appointment of Blaine McKee, Ph.D., Senior Vice President and Head of Transactions at Shire plc, to HART's Board of Directors. Dr. McKee has also been named to the Board's Audit Committee, bringing HART back into compliance with the Nasdaq Capital Market's requirement for audit committee composition.
HART: 1.79 (+0.14)
Bioengineered Organ Implant Developer HART To Host Q4 2015 Conference Call Thursday, March 17th at 5:00pm ET
PR Newswire - Tue Mar 08, 7:30AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, will announce results of its fourth quarter and year ended December 31, 2015 and provide business commentary after market trading hours on Thursday, March 17, 2016. A conference call to discuss the company's fourth quarter and fiscal year 2015 results and business outlook is scheduled for that same day at 5:00 PM (Eastern Time). On that call, management may respond to questions from the audience on any of a number of topics related to the business, including clinical and preclinical research, operations, plans and outlook.
HART: 1.79 (+0.14)
Bioengineered Organ Implant Developer HART to Webcast BIO CEO Conference Presentation Tues., Feb. 9th at 8:00 am EST
PR Newswire - Wed Feb 03, 12:34PM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today announced that CEO Jim McGorry, will present at the BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 8:00 am EST in New York City. HART's presentation will be webcast live and available for replay.
HART: 1.79 (+0.14)
Bioengineered Organ Implant Developer HART to Webcast Source Capital Disruptive Growth & Healthcare Conference Presentation Wed., Feb. 10th at 3:30 pm EST
PR Newswire - Mon Feb 01, 2:58PM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today announced that CEO Jim McGorry will present at the Source Capital Disruptive Growth & Healthcare Conference in New York City on Wednesday, February 10, 2016 at 3:30 pm EST. HART's presentation will be webcast live and available for replay.
HART: 1.79 (+0.14)
HART and Mayo Clinic Confirm Dates for Collaborative Large-Animal Bioengineered Organ Implant Surgeries
PR Newswire - Thu Jan 07, 3:15PM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today provided an update on large-animal studies being conducted with its co-development collaborator, Mayo Clinic.
HART: 1.79 (+0.14)
Bioengineered Organ Implant Developer HART to Webcast Biotech Showcase(TM) Presentation Monday, Jan. 11 at 2:00 pm PT
PR Newswire - Wed Dec 30, 8:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today announced that its CEO Jim McGorry will present at the 8th annual Biotech Showcase conference on Monday, January 11th at 2:00 pm. Pacific Time. Mr. McGorry, Dr. Saverio La Francesca, HART's Chief Medical Officer, and Tom McNaughton, HART's CFO, will also be available for investment community meetings in San Francisco Monday, January 11th through Wednesday, January 13th - contact investor relations (below) to schedule a meeting.
HART: 1.79 (+0.14)
HART Secures Common Stock Purchase Facility with Aspire Capital
PR Newswire - Tue Dec 15, 3:56PM CST
Harvard Apparatus Regenerative Technology, Inc. (HART) (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for the esophagus, trachea and bronchus, today announced that it has entered into a two and a half year, $15.0 million common stock purchase agreement with Aspire Capital Fund, LLC, pursuant to which HART has completed an initial sale of 500,000 shares at $2.00 per share. Proceeds from the facility will be used to fund HART's general corporate purposes, including research, development and commercialization activities.
HART: 1.79 (+0.14)
HART's CMO Dr. Saverio La Francesca to moderate panel on "Regenerative Engineering and Bio-Materials" at World Stem Cell Summit Saturday, Dec. 12
PR Newswire - Tue Dec 08, 10:54AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today announced that Executive Vice President and Chief Medical Officer Saverio La Francesca, MD will moderate and speak at the World Stem Cell Summit during a secession entitled "Regenerative Engineering and Bio-Materials" on Saturday, December 12, 2015 at 2:00 p.m. ET. The conference will be held at the Hyatt Regency in Atlanta, GA.
HART: 1.79 (+0.14)
Bioengineered Organ Implant Company HART to Present at RegMed Capital Conference in Atlanta, Friday Dec. 11 at 9:00 am ET
PR Newswire - Thu Dec 03, 11:16AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today announced that CEO Jim McGorry will present at the RegMed Capital Conference on Friday, December 11, 2015 at 9:00 a.m. ET.. The conference will be held at the Hyatt Regency in Atlanta, GA co-located with the World Stem Cell Summit.
HART: 1.79 (+0.14)
HART Regains Compliance With Nasdaq Minimum Bid Price Listing Rule
PR Newswire - Mon Nov 30, 3:21PM CST
Harvard Apparatus Regenerative Technology, Inc. (HART) (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today announced it has received written notification from The NASDAQ Stock Market that it has regained compliance with the minimum bid price requirements. The letter noted that as a result of the closing bid price of HART's common stock having exceeded $1.00 per share for more than ten consecutive business days, the company has regained compliance and the matter is now closed.
HART: 1.79 (+0.14)
Bioengineered Organ Implant Company HART to Webcast LD Micro Presentation in Los Angeles, Tues. Dec. 1st at 2:30 pm PT
PR Newswire - Wed Nov 25, 12:56PM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today announced that CEO Jim McGorry will present at the LD Micro "Main Event" investor conference on Tuesday, December 1, 2015 at 2:30 p.m. PT. The presentation will be webcast live and posted for replay (link below) for 30 days. Management will also be available at the conference for one-on-one meetings on Wednesday, December 2, 2015. The conference will be held at the Luxe Sunset Bel Air Hotel in Los Angeles, CA.
HART: 1.79 (+0.14)
Health-Care Defies Economic Conditions and Moves to New Highs - Broad Street Alerts
ACCESSWIRE - Tue Nov 17, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / November 17, 2015 / Harvard Apparatus Regenerative Technology Inc. (NASDAQ: HART), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Aeterna Zentaris Inc. (NASDAQ: AEZS), and KaloBios Pharmaceuticals Inc. (NSADQ: KBIO) are four tickers in the health-care space taking part in the bustling M&A activity the sector experienced in the past year. The sector faced recent pressure caused by price gouging and reactions from politicians against 'big pharma' monopolies. However, the health-care sector has thrived nonetheless with in unfavorable economic conditions and has outperformed all other sectors. This presents investors with opportunities for spotting takeover candidates while earning significant returns from holding the large caps as well.
AEZS: 3.44 (+0.07), HART: 1.79 (+0.14), ARNA: 1.68 (+0.01)
HART Reports Q3 Financial Results and Provides Business Update
PR Newswire - Thu Nov 12, 3:05PM CST
Harvard Apparatus Regenerative Technology, Inc. (HART) (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today reported third quarter financial results and provided a business update. Separately this morning, HART reported significant results from research involving its second-generation (Gen2) bioengineered trachea, bronchus and esophagus implants in large animals (Click here for release). HART will host a conference call today at 5:00 pm ET to review its results, progress and outlook (details below).
HART: 1.79 (+0.14)
HART Reports Significant Confirmatory Results for its 2nd Generation Bioengineered Esophagus, Trachea and Bronchus Implants
PR Newswire - Thu Nov 12, 7:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (HART) (Nasdaq: HART), a biotechnology company developing bioengineered implants for life-threatening conditions, today announced significant results - including clear evidence of complete esophageal tissue regeneration - from recently conducted animal research on HART's 2nd Generation (Gen2) bioengineered implant platform. HART will hold a conference call at 5:00 p.m. ET today to discuss these results.
HART: 1.79 (+0.14)
Tissue Engineering Pioneer Dr. Joseph P. Vacanti Agrees to Chair New Scientific Advisory Board for Bioengineered Organ Developer HART
PR Newswire - Wed Nov 11, 10:56AM CST
Harvard Apparatus Regenerative Technology, Inc. ("HART"
(NASDAQ: HART), a biotechnology company developing bioengineered organs for life-threatening conditions, announced today that Joseph P. (Jay) Vacanti, M.D., a surgeon and pioneering scientist in the field of tissue engineering, has agreed to serve as Chairman of HART's newly launched Scientific Advisory Board. Final details of Dr. Vacanti's appointment are subject to approval by Massachusetts General Hospital and Partners Healthcare, a non-profit healthcare system and leader in biomedical research founded by Massachusetts General Hospital and Brigham and Women's Hospital. The Advisory Board's role is to provide support and guidance for HART's research and development programs. The Company expects to add three to five additional members to the Advisory Board over the next twelve to eighteen months.
HART: 1.79 (+0.14)
Nasdaq Provides HART With 180-Day Period in Which to Regain Compliance With $1.00 Minimum Closing Bid Price Rule
Marketwired - Tue Nov 10, 3:44PM CST
Harvard Apparatus Regenerative Technology, Inc. ("HART" (NASDAQ: HART), a biotechnology company developing bioengineered organs for life-threatening conditions, announced today that it has received a continued listing deficiency notice from The NASDAQ Stock Market LLC because its share price has not met the $1.00 minimum closing bid price requirement for 30 consecutive business days [Nasdaq Listing Rule 5450(a)(1)]. This notice has no immediate effect on the Company's Nasdaq listing or the trading of its common stock.
HART: 1.79 (+0.14)
Harvard Apparatus Regenerative Technology Schedules Release of Third Quarter 2015 Financial Results and Investor Teleconference for November 12th
BusinessWire - Fri Oct 30, 2:28PM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a biotechnology company developing bioengineered organs for life-threatening conditions, will announce results of its third quarter ended September 30, 2015 and business update after market trading hours on Thursday, November 12, 2015. A conference call to discuss the company's third quarter results and business outlook is scheduled for that same day at 5:00 PM (Eastern Time). On that call, management may respond to questions from the audience on any of a number of topics related to the business, including clinical and preclinical research, operations, plans and outlook.
HART: 1.79 (+0.14)
Harvard Apparatus Regenerative Technology Provides Business Update and Reports Second Quarter 2015 Financial Results
BusinessWire - Thu Aug 13, 3:05PM CDT
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), or HART, a biotechnology company developing bioengineered organs for life-threatening conditions, today provided a business update and reported unaudited financial results for the three months ended June 30, 2015.
HART: 1.79 (+0.14)
Harvard Apparatus Regenerative Technology Changes Name to Biostage, Inc. (NASDAQ: BSTG)
PR Newswire - Thu Mar 31, 7:00AM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART) announced today it has changed its corporate name to Biostage, Inc. and will trade under the Nasdaq symbol "BSTG" effective April 1, 2016. Concurrently, the company has launched a new web site www.biostage.com to provide greater clarity and visibility for its technology.
HART: 1.79 (+0.14)
Bioengineered Organ Implant Developer HART Reviews Progress and Q4 2015 Results
PR Newswire - Thu Mar 17, 3:21PM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), announced its financial results for the fourth quarter and year ended December 31, 2015 and reviewed its corporate and research progress and plans.
HART: 1.79 (+0.14)
Bioengineered Organ Implant Developer HART Names Accomplished Biotechnology Executive Dr. Blaine McKee to its Board
PR Newswire - Thu Mar 10, 10:06AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today announced the appointment of Blaine McKee, Ph.D., Senior Vice President and Head of Transactions at Shire plc, to HART's Board of Directors. Dr. McKee has also been named to the Board's Audit Committee, bringing HART back into compliance with the Nasdaq Capital Market's requirement for audit committee composition.
HART: 1.79 (+0.14)
Bioengineered Organ Implant Developer HART To Host Q4 2015 Conference Call Thursday, March 17th at 5:00pm ET
PR Newswire - Tue Mar 08, 7:30AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, will announce results of its fourth quarter and year ended December 31, 2015 and provide business commentary after market trading hours on Thursday, March 17, 2016. A conference call to discuss the company's fourth quarter and fiscal year 2015 results and business outlook is scheduled for that same day at 5:00 PM (Eastern Time). On that call, management may respond to questions from the audience on any of a number of topics related to the business, including clinical and preclinical research, operations, plans and outlook.
HART: 1.79 (+0.14)
Bioengineered Organ Implant Developer HART to Webcast BIO CEO Conference Presentation Tues., Feb. 9th at 8:00 am EST
PR Newswire - Wed Feb 03, 12:34PM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today announced that CEO Jim McGorry, will present at the BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 8:00 am EST in New York City. HART's presentation will be webcast live and available for replay.
HART: 1.79 (+0.14)
Bioengineered Organ Implant Developer HART to Webcast Source Capital Disruptive Growth & Healthcare Conference Presentation Wed., Feb. 10th at 3:30 pm EST
PR Newswire - Mon Feb 01, 2:58PM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today announced that CEO Jim McGorry will present at the Source Capital Disruptive Growth & Healthcare Conference in New York City on Wednesday, February 10, 2016 at 3:30 pm EST. HART's presentation will be webcast live and available for replay.
HART: 1.79 (+0.14)
HART and Mayo Clinic Confirm Dates for Collaborative Large-Animal Bioengineered Organ Implant Surgeries
PR Newswire - Thu Jan 07, 3:15PM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today provided an update on large-animal studies being conducted with its co-development collaborator, Mayo Clinic.
HART: 1.79 (+0.14)
Bioengineered Organ Implant Developer HART to Webcast Biotech Showcase(TM) Presentation Monday, Jan. 11 at 2:00 pm PT
PR Newswire - Wed Dec 30, 8:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today announced that its CEO Jim McGorry will present at the 8th annual Biotech Showcase conference on Monday, January 11th at 2:00 pm. Pacific Time. Mr. McGorry, Dr. Saverio La Francesca, HART's Chief Medical Officer, and Tom McNaughton, HART's CFO, will also be available for investment community meetings in San Francisco Monday, January 11th through Wednesday, January 13th - contact investor relations (below) to schedule a meeting.
HART: 1.79 (+0.14)
HART Secures Common Stock Purchase Facility with Aspire Capital
PR Newswire - Tue Dec 15, 3:56PM CST
Harvard Apparatus Regenerative Technology, Inc. (HART) (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for the esophagus, trachea and bronchus, today announced that it has entered into a two and a half year, $15.0 million common stock purchase agreement with Aspire Capital Fund, LLC, pursuant to which HART has completed an initial sale of 500,000 shares at $2.00 per share. Proceeds from the facility will be used to fund HART's general corporate purposes, including research, development and commercialization activities.
HART: 1.79 (+0.14)
HART's CMO Dr. Saverio La Francesca to moderate panel on "Regenerative Engineering and Bio-Materials" at World Stem Cell Summit Saturday, Dec. 12
PR Newswire - Tue Dec 08, 10:54AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today announced that Executive Vice President and Chief Medical Officer Saverio La Francesca, MD will moderate and speak at the World Stem Cell Summit during a secession entitled "Regenerative Engineering and Bio-Materials" on Saturday, December 12, 2015 at 2:00 p.m. ET. The conference will be held at the Hyatt Regency in Atlanta, GA.
HART: 1.79 (+0.14)
Bioengineered Organ Implant Company HART to Present at RegMed Capital Conference in Atlanta, Friday Dec. 11 at 9:00 am ET
PR Newswire - Thu Dec 03, 11:16AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today announced that CEO Jim McGorry will present at the RegMed Capital Conference on Friday, December 11, 2015 at 9:00 a.m. ET.. The conference will be held at the Hyatt Regency in Atlanta, GA co-located with the World Stem Cell Summit.
HART: 1.79 (+0.14)
HART Regains Compliance With Nasdaq Minimum Bid Price Listing Rule
PR Newswire - Mon Nov 30, 3:21PM CST
Harvard Apparatus Regenerative Technology, Inc. (HART) (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today announced it has received written notification from The NASDAQ Stock Market that it has regained compliance with the minimum bid price requirements. The letter noted that as a result of the closing bid price of HART's common stock having exceeded $1.00 per share for more than ten consecutive business days, the company has regained compliance and the matter is now closed.
HART: 1.79 (+0.14)
Bioengineered Organ Implant Company HART to Webcast LD Micro Presentation in Los Angeles, Tues. Dec. 1st at 2:30 pm PT
PR Newswire - Wed Nov 25, 12:56PM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today announced that CEO Jim McGorry will present at the LD Micro "Main Event" investor conference on Tuesday, December 1, 2015 at 2:30 p.m. PT. The presentation will be webcast live and posted for replay (link below) for 30 days. Management will also be available at the conference for one-on-one meetings on Wednesday, December 2, 2015. The conference will be held at the Luxe Sunset Bel Air Hotel in Los Angeles, CA.
HART: 1.79 (+0.14)
Health-Care Defies Economic Conditions and Moves to New Highs - Broad Street Alerts
ACCESSWIRE - Tue Nov 17, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / November 17, 2015 / Harvard Apparatus Regenerative Technology Inc. (NASDAQ: HART), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Aeterna Zentaris Inc. (NASDAQ: AEZS), and KaloBios Pharmaceuticals Inc. (NSADQ: KBIO) are four tickers in the health-care space taking part in the bustling M&A activity the sector experienced in the past year. The sector faced recent pressure caused by price gouging and reactions from politicians against 'big pharma' monopolies. However, the health-care sector has thrived nonetheless with in unfavorable economic conditions and has outperformed all other sectors. This presents investors with opportunities for spotting takeover candidates while earning significant returns from holding the large caps as well.
AEZS: 3.44 (+0.07), HART: 1.79 (+0.14), ARNA: 1.68 (+0.01)
HART Reports Q3 Financial Results and Provides Business Update
PR Newswire - Thu Nov 12, 3:05PM CST
Harvard Apparatus Regenerative Technology, Inc. (HART) (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today reported third quarter financial results and provided a business update. Separately this morning, HART reported significant results from research involving its second-generation (Gen2) bioengineered trachea, bronchus and esophagus implants in large animals (Click here for release). HART will host a conference call today at 5:00 pm ET to review its results, progress and outlook (details below).
HART: 1.79 (+0.14)
HART Reports Significant Confirmatory Results for its 2nd Generation Bioengineered Esophagus, Trachea and Bronchus Implants
PR Newswire - Thu Nov 12, 7:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (HART) (Nasdaq: HART), a biotechnology company developing bioengineered implants for life-threatening conditions, today announced significant results - including clear evidence of complete esophageal tissue regeneration - from recently conducted animal research on HART's 2nd Generation (Gen2) bioengineered implant platform. HART will hold a conference call at 5:00 p.m. ET today to discuss these results.
HART: 1.79 (+0.14)
Tissue Engineering Pioneer Dr. Joseph P. Vacanti Agrees to Chair New Scientific Advisory Board for Bioengineered Organ Developer HART
PR Newswire - Wed Nov 11, 10:56AM CST
Harvard Apparatus Regenerative Technology, Inc. ("HART"
(NASDAQ: HART), a biotechnology company developing bioengineered organs for life-threatening conditions, announced today that Joseph P. (Jay) Vacanti, M.D., a surgeon and pioneering scientist in the field of tissue engineering, has agreed to serve as Chairman of HART's newly launched Scientific Advisory Board. Final details of Dr. Vacanti's appointment are subject to approval by Massachusetts General Hospital and Partners Healthcare, a non-profit healthcare system and leader in biomedical research founded by Massachusetts General Hospital and Brigham and Women's Hospital. The Advisory Board's role is to provide support and guidance for HART's research and development programs. The Company expects to add three to five additional members to the Advisory Board over the next twelve to eighteen months. HART: 1.79 (+0.14)
Nasdaq Provides HART With 180-Day Period in Which to Regain Compliance With $1.00 Minimum Closing Bid Price Rule
Marketwired - Tue Nov 10, 3:44PM CST
Harvard Apparatus Regenerative Technology, Inc. ("HART"
(NASDAQ: HART), a biotechnology company developing bioengineered organs for life-threatening conditions, announced today that it has received a continued listing deficiency notice from The NASDAQ Stock Market LLC because its share price has not met the $1.00 minimum closing bid price requirement for 30 consecutive business days [Nasdaq Listing Rule 5450(a)(1)]. This notice has no immediate effect on the Company's Nasdaq listing or the trading of its common stock. HART: 1.79 (+0.14)
Harvard Apparatus Regenerative Technology Schedules Release of Third Quarter 2015 Financial Results and Investor Teleconference for November 12th
BusinessWire - Fri Oct 30, 2:28PM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a biotechnology company developing bioengineered organs for life-threatening conditions, will announce results of its third quarter ended September 30, 2015 and business update after market trading hours on Thursday, November 12, 2015. A conference call to discuss the company's third quarter results and business outlook is scheduled for that same day at 5:00 PM (Eastern Time). On that call, management may respond to questions from the audience on any of a number of topics related to the business, including clinical and preclinical research, operations, plans and outlook.
HART: 1.79 (+0.14)
Harvard Apparatus Regenerative Technology Provides Business Update and Reports Second Quarter 2015 Financial Results
BusinessWire - Thu Aug 13, 3:05PM CDT
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), or HART, a biotechnology company developing bioengineered organs for life-threatening conditions, today provided a business update and reported unaudited financial results for the three months ended June 30, 2015.
HART: 1.79 (+0.14)
